An American company called Genomic Health has been collaborating with Pfizer over the past 10 years to develop a 16-gene expression test to determine the chances of recurrence of kidney cancer after surgery.
The test was validated in a study, which was published in The Lancet Oncology in 2015. The validation study showed that the test’s recurrence score provided information on which clinically high-risk, stage III kidney cancer patients would experience recurrence following surgery. However, the study did not confirm the test’s ability to predict which patients would benefit from adjuvant treatment (treatment after surgery) with Pfizer’s Sutent (sunitinib).
The test will not be commercialised until adjuvant treatments for kidney cancer are routinely available on the market.